School of Medicine

Wayne State University School of Medicine

CAMPATH II – A yearly infusion or treatment with Rebif® in MS patients who have been on therapy- Closed to Enrollment

This is a multi-center study which will examine the safety and compare the efficacy of low and high dose alemtuzumab (Campath®) to interferon beta-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients who have previously relapsed while on a disease modifying therapy. Patients will be randomly assigned to receive 2 annual cycles of intravenous low (12mg) or high (24mg) dose alemtuzumab (daily IV infusion for 5 consecutive days at Month 0 and daily infusion for 3 consecutive days at Month 12), or 3 weekly subcutaneous Rebif® injections. The study will end 2 years after the last patient has been randomized.

Eligibility: Patients who have relapsed while on an MS therapy, 18-50 yrs old diagnosed with RRMS with an onset of MS symptoms within 5 years of screening. Patients must be able to walk at least 200 meters without aid or rest and have experienced ≥2 MS relapses in the past 24 months, which were confirmed by a physician.

For more information visit: CAMMS32400507 (CARE-MS II)